4-甲氧基噻吩-3-羧酸甲酯 | 65369-22-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-甲氧基噻吩-3-羧酸甲酯
• 中文别名: 4-甲氧基噻吩-3-甲酸甲酯
• 英文名称: methyl 4-methoxy-3-thiophenecarboxylate
• 英文别名: methyl 4-methoxythiophene-3-carboxylate
• CAS: 65369-22-4
• 化学式: C₇H₈O₃S
• mdl: MFCD00067995
• 分子量: 172.205
• InChiKey: LQIVVUILGDRRHE-UHFFFAOYSA-N

物化性质

• 熔点：
  70 °C
• 沸点：
  248.1±20.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  63.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 安全说明：
  S24/25,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 储存条件：
  室温

SDS

Name:	Methyl 4-methoxythiophene-3-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	65369-22-4

Section 1 - Chemical Product MSDS Name:Methyl 4-methoxythiophene-3-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
65369-22-4	Methyl 4-methoxythiophene-3-carboxylat	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 65369-22-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 73 - 73 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8O3S
Molecular Weight: 172

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 65369-22-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 4-methoxythiophene-3-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 65369-22-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 65369-22-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 65369-22-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲氧基噻吩-3-羧酸甲酯 以89%的产率得到
  参考文献：
  名称：

  PRESS J. B.; HOFMANN C. M.; SAFIR S. R., J. ORG. CHEM., 1979, 44, NO 19, 3292-3296

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl 2,5-dihydro-4-methoxythiophene-3-carboxylate 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以93%的产率得到4-甲氧基噻吩-3-羧酸甲酯
  参考文献：
  名称：

  Aromatization of dihydrothiophenes. Thiophenesaccharin: a sweet surprise

  摘要：

  DOI：

  10.1021/jo01292a012

文献信息

• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• Cycloalkyl tachykinin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05750549A1

  公开（公告）日：1998-05-12

  The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

  本发明涉及由结构式I表示的某些新化合物：##STR1##或其药学上可接受的盐，其中R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.11、R.sup.12、R.sup.13、A、Q、W、X、Y、Z和n在此处定义。本发明还涉及包含这些新化合物作为活性成分的药物配方，以及在治疗某些疾病中使用这些新化合物及其配方。本发明的化合物是催吐肽受体拮抗剂，可用于治疗炎症性疾病、疼痛或偏头痛、哮喘和呕吐。
• Thiophene compounds and their manufacture
  申请人：BASF Aktiengesellschaft

  公开号：US04239897A1

  公开（公告）日：1980-12-16

  New thiophene compounds and a new process for the manufacture of thiophene compounds by dehydrogenating dihydrothiophene with certain halogen compounds. The products are starting materials for the manufacture of pharmaceuticals, dyes and plant protection agents and, in particular, for the manufacture of additives to foodstuffs, feeds, beverages and pharmaceuticals.

  新的噻吩化合物以及一种通过使用特定卤素化合物对二氢噻吩进行脱氢来制造噻吩化合物的新工艺。这些产品是制造药品、染料和植物保护剂的起始材料，特别是用于制造食品、饲料、饮料和药品的添加剂。
• Synthesis and Biological Activity of Various Derivatives of a Novel Class of Potent, Selective, and Orally Active Prostaglandin D₂ Receptor Antagonists. 2. 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives
  作者：Susumu Mitsumori、Tatsuo Tsuri、Tsunetoshi Honma、Yoshiharu Hiramatsu、Toshihiko Okada、Hiroshi Hashizume、Shiro Kida、Masanao Inagaki、Akinori Arimura、Kiyoshi Yasui、Fujio Asanuma、Junji Kishino、Mitsuaki Ohtani

  DOI：10.1021/jm0205189

  日期：2003.6.1

  an earlier paper, we reported that novel prostaglandin D(2) (PGD(2)) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD(2) receptor antagonists having the 6

  在较早的论文中，我们报道了以双环[2.2.1]庚烷环系统为前列腺素骨架的新型前列腺素D（2）（PGD（2））受体拮抗剂是一种有效的新型抗过敏剂，可抑制各种过敏性炎症诸如在结膜炎和哮喘模型中观察到的反应。在本研究中，我们合成了具有6,6-二甲基双环[3.1.1]庚烷环系统的PGD（2）受体拮抗剂。与具有磺酰胺基的双环[2.2.1]庚烷环系统的那些相反，这些衍生物具有酰胺部分。具有6,6-二甲基双环[3.1.1]庚烷环的衍生物在PGD（2）受体结合和cAMP形成分析中也显示出强大的活性。在诸如过敏性鼻炎，结膜炎和哮喘模型等体内分析中，这些系列的衍生物显示出优异的药理特性。特别地，化合物45在过敏性鼻炎和哮喘模型中也有效抑制了嗜酸性粒细胞的浸润。该化合物（45，S-5751）现在正被开发为一种有前途的抗过敏药物候选物。
• Organic compounds and their use as pharmaceuticals
  申请人：Lilly S.A.

  公开号：US05015656A1

  公开（公告）日：1991-05-14

  A pharmaceutical compound of the formula ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 independently are hydrogen, hydroxy, halo, nitro, amino, C.sub.2-5 acylamino, C.sub.1-4 alkyl, --CHO, --CH.sub.2 OH, --CH.sub.2 OC.sub.1-4 alkyl, --COOH, --COC.sub.1-3 alkyl, --CH(OH)C.sub.1-3 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphinyl, C.sub.1-4 alkylsulphonyl, N-substituted heterocyclyl, optionally substituted phenyl, optionally substituted phenylthio, optionally substituted phenylsulphinyl, optionally substituted phenylsulphonyl or optionally substituted phenylsulphonamido, or R.sup.1 and R.sup.2 together form a C.sub.3-5 alkylene bridge; provided that at least one of R.sup.2 and R.sup.3 is C.sub.1-4 alkoxy or C.sub.2-4 alkenyloxy; and X is (i) --(CH.sub.2).sub.n N(R.sup.4).sub.2 where each R.sup.4 independently is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or optionally substituted C.sub.6 H.sub.5 CH.sub.2 --, and n is 1, 2 or 3, or (ii) a 5- to 8-membered alicyclic group containing one or two nitrogen atoms and directly attached to the amido nitrogen or attached by a C.sub.1-3 alkylene chain; and salts and esters thereof.

  化学式为##STR1##的药物化合物，其中R.sup.1，R.sup.2和R.sup.3独立地是氢，羟基，卤素，硝基，氨基，C.sub.2-5酰胺基，C.sub.1-4烷基，--CHO，--CH.sub.2 OH，--CH.sub.2 OC.sub.1-4烷基，--COOH，--COC.sub.1-3烷基，--CH(OH)C.sub.1-3烷基，C.sub.1-4烷氧基，C.sub.2-4烯基氧基，C.sub.1-4烷基硫基，C.sub.1-4烷基磺酰基，C.sub.1-4烷基磺基，N-取代的杂环基，可选择取代的苯基，可选择取代的苯基硫基，可选择取代的苯基磺酰基，可选择取代的苯基磺胺基，或者R.sup.1和R.sup.2共同形成一个C.sub.3-5烷基桥；前提是R.sup.2和R.sup.3中至少有一个是C.sub.1-4烷氧基或C.sub.2-4烯基氧基；X为(i)--(CH.sub.2).sub.n N(R.sup.4).sub.2，其中每个R.sup.4独立地是C.sub.1-4烷基，C.sub.2-4烯基或可选择取代的C.sub.6 H.sub.5 CH.sub.2 --，n为1, 2或3，或者(ii)一个含有一个或两个氮原子的5-到8-成员的脂环基，直接连接到酰胺氮或通过一个C.sub.1-3烷基链连接；以及其盐和酯。